A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed renal cell carcinoma
except medullary or collecting duct subtypes; sarcomatoid differentiation will be
allowed

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional
techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic
resonance imaging (MRI), or calipers by clinical exam

- Patients must have documented radiologic or clinical progressive disease following at
least one prior anti-VEGF regimen administered either as a single agent or in
combination with other agents for at least 8 weeks; the immediate prior treatment
regimen must have included bevacizumab, pazopanib, sorafenib or sunitinib
administered not more than 12 weeks before study entry; note: enrollment not more
than 8 weeks after the last dose of anti-VEGF therapy is encouraged

- Any number of prior regimens is allowed; prior investigational therapy is allowed

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

- Life expectancy of greater than 3 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
=< 2.5 X institutional upper limit of normal

- Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) =<
upper limit of normal (ULN) per institutional laboratory range and international
normalized ratio (INR) =< 1.5

- Creatinine within normal institutional limits or creatinine clearance > 60 mL/min per
24 h urine collection or calculated according to the Cockcroft-Gault formula

- Urinary protein =< 100 mg/dL in urinalysis or =< 1+ on dipstick, unless quantitative
protein is < 1000 mg in a 24 h urine sample

- Generally well-controlled blood pressure with systolic blood pressure =< 140 mmHg AND
diastolic blood pressure =< 90 mmHg prior to enrollment; the use of anti-hypertensive
medications to control hypertension is permitted

- Patients must have a tumor site amenable to biopsy as determined by the treating
investigator; any questions regarding suitability of a site for biopsy will be
adjudicated by the principal investigator

- Patients must be willing to consent to tumor biopsy for research purposes

- Patients should have archival tumor tissue (either unstained slides or tumor blocks)
available for retrieval

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation, and 6 months after completion of AMG 386; should
a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately;
men treated or enrolled on this protocol must also agree to use adequate
contraception prior to the study, for the duration of study participation, and 6
months after completion of AMG 386 and bevacizumab, pazopanib, sunitinib, or
sorafenib administration

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Intolerance of the immediate prior treatment with bevacizumab, pazopanib, sorafenib,
or sunitinib; note: subjects who required a dose reduction of pazopanib, sorafenib,
or sunitinib during prior therapy MAY be eligible if they tolerated the agent after
dose level reduction (to a minimum of dose level -2 as defined in this protocol)

- Central nervous system metastases unless: (1) metastases have been treated and have
remained controlled for at least two weeks following treatment, AND (2) patient has
no residual neurological dysfunction off corticosteroids for at least one week; a CT
or MRI to evaluate for central nervous system (CNS) disease is required for
symptomatic patients only

- History of venous or arterial thromboembolism within 12 months prior to
enrollment/randomization

- History of clinically significant bleeding within 6 months of
enrollment/randomization

- Unresolved toxicities from prior systemic therapy that are Common Terminology
Criteria in Adverse Events (CTCAE) version 3.0 or 4.0 >= grade 2 in severity except
alopecia

- Currently or previously treated with AMG 386, or other molecules that inhibit the
angiopoietins or Tie2 receptor

- Clinically significant cardiovascular disease within 12 months prior to
enrollment/randomization, including myocardial infarction, unstable angina, grade 2
or greater peripheral vascular disease, cerebrovascular accident, transient ischemic
attack, congestive heart failure, or arrhythmias not controlled by outpatient
medication or placement of percutaneous transluminal coronary angioplasty/stent

- Major surgery within 28 days prior to enrollment or still recovering from prior
surgery

- Minor surgical procedures except placement of tunneled central venous access device
within 3 days prior to enrollment

- Non-healing wound, ulcer (including gastrointestinal), or fracture

- Subject not consenting to the use of highly effective contraceptive precautions
(e.g., double barrier method [i.e., condom plus diaphragm]) during the course of the
study and for 6 months after administration of the last study medication

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to AMG 386 or the anti-VEGF agent used in study

- History of allergic reactions to bacterially-produced proteins

- Patients who have had anti-VEGFR tyrosine kinase inhibitor within 1 week or anti-VEGF
antibody therapy within 3 weeks prior to entering the study; patients who have had
other forms of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas
or mitomycin C) prior to entering the study or those who have not recovered from
adverse events due to agents administered more than 4 weeks earlier

- Patients who have not yet completed at least 21 days (30 days for prior monoclonal
antibody therapy) since ending other investigational device or drug trials, or who
are currently receiving other investigational treatments

- Patients receiving any medications or substances that are strong inhibitors or
inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP450 3A4) are
ineligible; caution is advised for patients requiring weak or moderate CYP450 3A4
inhibitors or inducers; specifically prohibited medicines include indinavir,
nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone,
carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St.
John's wort, and troglitazone

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study; breastfeeding must be discontinued if
the mother is treated with AMG 386

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible; appropriate studies will be undertaken in patients receiving
combination antiretroviral therapy when indicated

- Inability to take oral medications on a continuous basis; patients who are to take
pazopanib, sorafenib, or sunitinib and are unable to swallow pills whole are
ineligible (the pills cannot be crushed or broken)

- Any condition which in the investigator's opinion makes the subject unsuitable for
study participation